Literature DB >> 1639952

Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.

S Zimmermann1, R A Phillips, A Dunaif, D T Finegood, C Wilkenfeld, M Ardeljan, R Gorlin, L R Krakoff.   

Abstract

It has been hypothesized that insulin resistance and hyperinsulinemia contribute to the development of arterial hypertension. To further investigate this relationship, we compared arterial blood pressure in controls and women with polycystic ovary syndrome (PCO), an insulin-resistant state. Fourteen PCO women and 18 normal control women of similar age, body mass index, and race were studied. Plasma glucose and insulin levels were determined in an oral glucose tolerance test. The insulin sensitivity (SI) index was determined by the minimal model method. Systolic and diastolic blood pressure were measured by 24-h ambulatory monitoring. Left ventricular mass was assessed by echocardiography. The two groups had comparable fasting glucose levels, but the 2-h postload glucose was higher in PCO (8.0 +/- 0.5 vs. 5.6 +/- 0.3 mmol/L; P less than 0.001). Compared to controls, PCO women were significantly more insulin resistant by fasting insulin, 2-h insulin concentrations, and SI (28.3 +/- 6.7 vs. 68.3 +/- 10.0 min-1/nmol.mL; P less than 0.01). Average ambulatory systolic (121 +/- 2 vs. 118 +/- 2 mm Hg) and diastolic (76 +/- 2 vs. 73 +/- 2 mm Hg) blood pressures were similar for PCO and control women. No difference was found in left ventricular mass. Therefore, despite profound insulin resistance and hyperinsulinemia, women with PCO do not have increased arterial pressure or left ventricular mass.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639952     DOI: 10.1210/jcem.75.2.1639952

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 2.  Insulin resistance and polycystic ovary syndrome.

Authors:  David A Ehrmann
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 3.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

4.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 5.  Amylin, amyloid and age-related disease.

Authors:  G J Cooper; C A Tse
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

6.  Role of metformin in the management of polycystic ovary syndrome.

Authors:  Hany Lashen
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

Review 7.  Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.

Authors:  H J Teede; S Hutchison; S Zoungas; C Meyer
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

8.  Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome.

Authors:  Abha Majumdar; Tejshree A Singh
Journal:  J Hum Reprod Sci       Date:  2009-01

9.  Self-Reported Polycystic Ovary Syndrome Is Associated With Hypertension: A Northern Finland Birth Cohort 1966 Study.

Authors:  Meri-Maija E Ollila; Kari Kaikkonen; Marjo-Riitta Järvelin; Heikki V Huikuri; Juha S Tapanainen; Stephen Franks; Terhi T Piltonen; Laure Morin-Papunen
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

Review 10.  Treatment of PCOS with metformin and other insulin-sensitizing agents.

Authors:  Emre Seli; Antoni J Duleba
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.